Loading…
No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA
Background Opioid analgesics have been a standard modality for postoperative pain management after total knee arthroplasty (TKA) but are also associated with increased risk of nausea, pruritus, vomiting, respiratory depression, prolonged ileus, and cognitive dysfunction. There is still a need for a...
Saved in:
Published in: | Clinical orthopaedics and related research 2017-01, Vol.475 (1), p.94-105 |
---|---|
Main Authors: | , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c529t-d18b158497f15a441dec690c62540661eeca604ba5e527913552e05cf9d88b3f3 |
---|---|
cites | cdi_FETCH-LOGICAL-c529t-d18b158497f15a441dec690c62540661eeca604ba5e527913552e05cf9d88b3f3 |
container_end_page | 105 |
container_issue | 1 |
container_start_page | 94 |
container_title | Clinical orthopaedics and related research |
container_volume | 475 |
creator | Barrington, John W. Emerson, Roger H. Lovald, Scott T. Lombardi, Adolph V. Berend, Keith R. |
description | Background
Opioid analgesics have been a standard modality for postoperative pain management after total knee arthroplasty (TKA) but are also associated with increased risk of nausea, pruritus, vomiting, respiratory depression, prolonged ileus, and cognitive dysfunction. There is still a need for a method of anesthesia that can deliver effective long-term postoperative pain relief without incurring the high cost and health burden of opioids and nerve blocks.
Questions/purposes
(1) Is liposomal bupivacaine-based periarticular injection (PAI) more effective than morphine-based spinal anesthesia or ropivacaine-based PAI in controlling postoperative pain after TKA? (2) Do patients treated with liposomal bupivacaine-based PAI experience fewer opioid-related adverse events compared with patients treated with morphine-based spinal anesthesia or ropivacaine-based PAI in controlling postoperative pain after TKA?
Methods
This multicenter, blind trial randomized 119 patients undergoing TKA with spinal anesthesia to receive spinal anesthesia plus periarticular injection with liposomal bupivacaine (40 patients), spinal anesthesia with bupivacaine plus intrathecal morphine (41 patients) but no liposomal bupivacaine injection, or spinal anesthesia with bupivacaine (38 patients) and no liposomal bupivacaine injection. The two groups that did not receive periarticular liposomal bupivacaine did receive periarticular injection with ropivacaine, and all three groups had ketorolac (30 mg) plus epinephrine (1:1000) in the periarticular injections. Patients in all three groups received identical perioperative multimodal analgesic and antiemetic drugs. All patients were analyzed in the group to which they were randomized and no patients were lost to followup. The primary study endpoints were visual analog score (VAS) for pain and narcotic use during postoperative day 1. Secondary endpoints included side effects associated with narcotic administration during the hospital stay.
Results
Mean VAS pain in the liposomal bupivacaine PAI group was lower than that for the ropivacaine PAI group at 6 hours (1.8 ± 2.1 versus 3.3 ± 2.3, p = 0.005, mean difference: 1.5, 95% confidence interval [CI], 0.5–2.5) and 12 hours (1.5 ± 2.0 versus 3.3 ± 2.4, p < 0.001, mean difference: 1.8, 95% CI, 0.8–2.8) after surgery. The morphine spinal group had lower pain compared with the liposomal bupivacaine PAI group at 6 hours (0.9 ± 1.8 versus 1.8 ± 2.1, p = 0.035, mean difference: 1.0, 95% CI, 0.1–1.8), b |
doi_str_mv | 10.1007/s11999-016-4931-z |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5174037</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1859497613</sourcerecordid><originalsourceid>FETCH-LOGICAL-c529t-d18b158497f15a441dec690c62540661eeca604ba5e527913552e05cf9d88b3f3</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhi0EokvhB3BBkbhwCXj8kcQXpG0pULHApUjcLK8z2fWStYOdFLW_HoctVUFC4mSN5pnHY7-EPAX6EiitXyUApVRJoSqF4lBe3yMLkKwpATi7TxaUUlUqBl-PyKOUdrnkQrKH5IjVnCtgYkG-fQrFG9d1GNFbLJwvzkzsr4qlN_0GkzPFCY4_EH2xckNIYW_64mQa3KWxxnkszv0O7eiCL4xvczVGM27RZupjiMN2RpbdiLG4-LB8TB50pk_45OY8Jl_enl2cvi9Xn9-dny5XpZVMjWULzRpkI1TdgTRCQIu2UtRWTApaVYBZX1GxNhIlqxVwKRlSaTvVNs2ad_yYvD54h2m9x9bivFWvh-j2Jl7pYJz-s-PdVm_CpZZQC8rrLHhxI4jh-4Rp1HuXLPa98RimpKGRKq9XAf8PlFU1FaqZ0ed_obswxfzPv4S0UkxylSk4UDaGlCJ2t3sD1XPq-pC6zqnrOXV9nWee3X3w7cTvmDPADkDKLb_BeOfqf1p_AtfDuCo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1850692539</pqid></control><display><type>article</type><title>No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA</title><source>Open Access: PubMed Central</source><creator>Barrington, John W. ; Emerson, Roger H. ; Lovald, Scott T. ; Lombardi, Adolph V. ; Berend, Keith R.</creator><creatorcontrib>Barrington, John W. ; Emerson, Roger H. ; Lovald, Scott T. ; Lombardi, Adolph V. ; Berend, Keith R.</creatorcontrib><description>Background
Opioid analgesics have been a standard modality for postoperative pain management after total knee arthroplasty (TKA) but are also associated with increased risk of nausea, pruritus, vomiting, respiratory depression, prolonged ileus, and cognitive dysfunction. There is still a need for a method of anesthesia that can deliver effective long-term postoperative pain relief without incurring the high cost and health burden of opioids and nerve blocks.
Questions/purposes
(1) Is liposomal bupivacaine-based periarticular injection (PAI) more effective than morphine-based spinal anesthesia or ropivacaine-based PAI in controlling postoperative pain after TKA? (2) Do patients treated with liposomal bupivacaine-based PAI experience fewer opioid-related adverse events compared with patients treated with morphine-based spinal anesthesia or ropivacaine-based PAI in controlling postoperative pain after TKA?
Methods
This multicenter, blind trial randomized 119 patients undergoing TKA with spinal anesthesia to receive spinal anesthesia plus periarticular injection with liposomal bupivacaine (40 patients), spinal anesthesia with bupivacaine plus intrathecal morphine (41 patients) but no liposomal bupivacaine injection, or spinal anesthesia with bupivacaine (38 patients) and no liposomal bupivacaine injection. The two groups that did not receive periarticular liposomal bupivacaine did receive periarticular injection with ropivacaine, and all three groups had ketorolac (30 mg) plus epinephrine (1:1000) in the periarticular injections. Patients in all three groups received identical perioperative multimodal analgesic and antiemetic drugs. All patients were analyzed in the group to which they were randomized and no patients were lost to followup. The primary study endpoints were visual analog score (VAS) for pain and narcotic use during postoperative day 1. Secondary endpoints included side effects associated with narcotic administration during the hospital stay.
Results
Mean VAS pain in the liposomal bupivacaine PAI group was lower than that for the ropivacaine PAI group at 6 hours (1.8 ± 2.1 versus 3.3 ± 2.3, p = 0.005, mean difference: 1.5, 95% confidence interval [CI], 0.5–2.5) and 12 hours (1.5 ± 2.0 versus 3.3 ± 2.4, p < 0.001, mean difference: 1.8, 95% CI, 0.8–2.8) after surgery. The morphine spinal group had lower pain compared with the liposomal bupivacaine PAI group at 6 hours (0.9 ± 1.8 versus 1.8 ± 2.1, p = 0.035, mean difference: 1.0, 95% CI, 0.1–1.8), but there was no difference at 12 hours (0.8 ± 1.5 versus 1.5 ± 2.0, p = 0.086, mean difference: 0.7, 95% CI, −0.1 to 1.5). The magnitude of the differences at 6 and 12 hours are near the lower end of minimal clinically important differences reported in the literature, and thus the improvement shown in this study may only represent a small clinical improvement. Both the liposomal bupivacaine group (13% [five of 40]) and the ropivacaine group (5% [two of 38]) had fewer incidents of itching (pruritus) than the spinal morphine group (38% [15 of 41]) (p = 0.001).
Conclusions
This prospective multicenter three-arm blind randomized controlled trial showed potentially improved pain control at 6 and 12 hours in the liposomal bupivacaine and intrathecal morphine groups compared with the ropivacaine group at the cost of much higher incidences of pruritus (itching) in the intrathecal morphine group. Based on these results, we prefer the use of PAI with liposomal bupivacaine as an alternative to spinal anesthesia with intrathecal morphine as a result of similar postoperative pain control and the potential for reducing adverse events.
Level of Evidence
Level I, therapeutic study.</description><identifier>ISSN: 0009-921X</identifier><identifier>EISSN: 1528-1132</identifier><identifier>DOI: 10.1007/s11999-016-4931-z</identifier><identifier>PMID: 27339124</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aged ; Analgesia, Patient-Controlled - methods ; Analgesics, Opioid - administration & dosage ; Analgesics, Opioid - therapeutic use ; Anesthetics, Local - administration & dosage ; Anesthetics, Local - therapeutic use ; Arthroplasty, Replacement, Knee - adverse effects ; Bupivacaine - administration & dosage ; Bupivacaine - therapeutic use ; Conservative Orthopedics ; Double-Blind Method ; Female ; Humans ; Injections, Spinal ; Liposomes ; Male ; Medicine ; Medicine & Public Health ; Middle Aged ; Morphine - administration & dosage ; Morphine - therapeutic use ; Orthopedics ; Pain Measurement ; Pain, Postoperative - drug therapy ; Sports Medicine ; Surgery ; Surgical Orthopedics ; Symposium: 2016 Knee Society Proceedings ; Treatment Outcome</subject><ispartof>Clinical orthopaedics and related research, 2017-01, Vol.475 (1), p.94-105</ispartof><rights>The Association of Bone and Joint Surgeons® 2016</rights><rights>Clinical Orthopaedics and Related Research is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c529t-d18b158497f15a441dec690c62540661eeca604ba5e527913552e05cf9d88b3f3</citedby><cites>FETCH-LOGICAL-c529t-d18b158497f15a441dec690c62540661eeca604ba5e527913552e05cf9d88b3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5174037/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5174037/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27339124$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Barrington, John W.</creatorcontrib><creatorcontrib>Emerson, Roger H.</creatorcontrib><creatorcontrib>Lovald, Scott T.</creatorcontrib><creatorcontrib>Lombardi, Adolph V.</creatorcontrib><creatorcontrib>Berend, Keith R.</creatorcontrib><title>No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA</title><title>Clinical orthopaedics and related research</title><addtitle>Clin Orthop Relat Res</addtitle><addtitle>Clin Orthop Relat Res</addtitle><description>Background
Opioid analgesics have been a standard modality for postoperative pain management after total knee arthroplasty (TKA) but are also associated with increased risk of nausea, pruritus, vomiting, respiratory depression, prolonged ileus, and cognitive dysfunction. There is still a need for a method of anesthesia that can deliver effective long-term postoperative pain relief without incurring the high cost and health burden of opioids and nerve blocks.
Questions/purposes
(1) Is liposomal bupivacaine-based periarticular injection (PAI) more effective than morphine-based spinal anesthesia or ropivacaine-based PAI in controlling postoperative pain after TKA? (2) Do patients treated with liposomal bupivacaine-based PAI experience fewer opioid-related adverse events compared with patients treated with morphine-based spinal anesthesia or ropivacaine-based PAI in controlling postoperative pain after TKA?
Methods
This multicenter, blind trial randomized 119 patients undergoing TKA with spinal anesthesia to receive spinal anesthesia plus periarticular injection with liposomal bupivacaine (40 patients), spinal anesthesia with bupivacaine plus intrathecal morphine (41 patients) but no liposomal bupivacaine injection, or spinal anesthesia with bupivacaine (38 patients) and no liposomal bupivacaine injection. The two groups that did not receive periarticular liposomal bupivacaine did receive periarticular injection with ropivacaine, and all three groups had ketorolac (30 mg) plus epinephrine (1:1000) in the periarticular injections. Patients in all three groups received identical perioperative multimodal analgesic and antiemetic drugs. All patients were analyzed in the group to which they were randomized and no patients were lost to followup. The primary study endpoints were visual analog score (VAS) for pain and narcotic use during postoperative day 1. Secondary endpoints included side effects associated with narcotic administration during the hospital stay.
Results
Mean VAS pain in the liposomal bupivacaine PAI group was lower than that for the ropivacaine PAI group at 6 hours (1.8 ± 2.1 versus 3.3 ± 2.3, p = 0.005, mean difference: 1.5, 95% confidence interval [CI], 0.5–2.5) and 12 hours (1.5 ± 2.0 versus 3.3 ± 2.4, p < 0.001, mean difference: 1.8, 95% CI, 0.8–2.8) after surgery. The morphine spinal group had lower pain compared with the liposomal bupivacaine PAI group at 6 hours (0.9 ± 1.8 versus 1.8 ± 2.1, p = 0.035, mean difference: 1.0, 95% CI, 0.1–1.8), but there was no difference at 12 hours (0.8 ± 1.5 versus 1.5 ± 2.0, p = 0.086, mean difference: 0.7, 95% CI, −0.1 to 1.5). The magnitude of the differences at 6 and 12 hours are near the lower end of minimal clinically important differences reported in the literature, and thus the improvement shown in this study may only represent a small clinical improvement. Both the liposomal bupivacaine group (13% [five of 40]) and the ropivacaine group (5% [two of 38]) had fewer incidents of itching (pruritus) than the spinal morphine group (38% [15 of 41]) (p = 0.001).
Conclusions
This prospective multicenter three-arm blind randomized controlled trial showed potentially improved pain control at 6 and 12 hours in the liposomal bupivacaine and intrathecal morphine groups compared with the ropivacaine group at the cost of much higher incidences of pruritus (itching) in the intrathecal morphine group. Based on these results, we prefer the use of PAI with liposomal bupivacaine as an alternative to spinal anesthesia with intrathecal morphine as a result of similar postoperative pain control and the potential for reducing adverse events.
Level of Evidence
Level I, therapeutic study.</description><subject>Aged</subject><subject>Analgesia, Patient-Controlled - methods</subject><subject>Analgesics, Opioid - administration & dosage</subject><subject>Analgesics, Opioid - therapeutic use</subject><subject>Anesthetics, Local - administration & dosage</subject><subject>Anesthetics, Local - therapeutic use</subject><subject>Arthroplasty, Replacement, Knee - adverse effects</subject><subject>Bupivacaine - administration & dosage</subject><subject>Bupivacaine - therapeutic use</subject><subject>Conservative Orthopedics</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Spinal</subject><subject>Liposomes</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Morphine - administration & dosage</subject><subject>Morphine - therapeutic use</subject><subject>Orthopedics</subject><subject>Pain Measurement</subject><subject>Pain, Postoperative - drug therapy</subject><subject>Sports Medicine</subject><subject>Surgery</subject><subject>Surgical Orthopedics</subject><subject>Symposium: 2016 Knee Society Proceedings</subject><subject>Treatment Outcome</subject><issn>0009-921X</issn><issn>1528-1132</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqNkU1v1DAQhi0EokvhB3BBkbhwCXj8kcQXpG0pULHApUjcLK8z2fWStYOdFLW_HoctVUFC4mSN5pnHY7-EPAX6EiitXyUApVRJoSqF4lBe3yMLkKwpATi7TxaUUlUqBl-PyKOUdrnkQrKH5IjVnCtgYkG-fQrFG9d1GNFbLJwvzkzsr4qlN_0GkzPFCY4_EH2xckNIYW_64mQa3KWxxnkszv0O7eiCL4xvczVGM27RZupjiMN2RpbdiLG4-LB8TB50pk_45OY8Jl_enl2cvi9Xn9-dny5XpZVMjWULzRpkI1TdgTRCQIu2UtRWTApaVYBZX1GxNhIlqxVwKRlSaTvVNs2ad_yYvD54h2m9x9bivFWvh-j2Jl7pYJz-s-PdVm_CpZZQC8rrLHhxI4jh-4Rp1HuXLPa98RimpKGRKq9XAf8PlFU1FaqZ0ed_obswxfzPv4S0UkxylSk4UDaGlCJ2t3sD1XPq-pC6zqnrOXV9nWee3X3w7cTvmDPADkDKLb_BeOfqf1p_AtfDuCo</recordid><startdate>20170101</startdate><enddate>20170101</enddate><creator>Barrington, John W.</creator><creator>Emerson, Roger H.</creator><creator>Lovald, Scott T.</creator><creator>Lombardi, Adolph V.</creator><creator>Berend, Keith R.</creator><general>Springer US</general><general>Lippincott Williams & Wilkins Ovid Technologies</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20170101</creationdate><title>No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA</title><author>Barrington, John W. ; Emerson, Roger H. ; Lovald, Scott T. ; Lombardi, Adolph V. ; Berend, Keith R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c529t-d18b158497f15a441dec690c62540661eeca604ba5e527913552e05cf9d88b3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Analgesia, Patient-Controlled - methods</topic><topic>Analgesics, Opioid - administration & dosage</topic><topic>Analgesics, Opioid - therapeutic use</topic><topic>Anesthetics, Local - administration & dosage</topic><topic>Anesthetics, Local - therapeutic use</topic><topic>Arthroplasty, Replacement, Knee - adverse effects</topic><topic>Bupivacaine - administration & dosage</topic><topic>Bupivacaine - therapeutic use</topic><topic>Conservative Orthopedics</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Spinal</topic><topic>Liposomes</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Morphine - administration & dosage</topic><topic>Morphine - therapeutic use</topic><topic>Orthopedics</topic><topic>Pain Measurement</topic><topic>Pain, Postoperative - drug therapy</topic><topic>Sports Medicine</topic><topic>Surgery</topic><topic>Surgical Orthopedics</topic><topic>Symposium: 2016 Knee Society Proceedings</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Barrington, John W.</creatorcontrib><creatorcontrib>Emerson, Roger H.</creatorcontrib><creatorcontrib>Lovald, Scott T.</creatorcontrib><creatorcontrib>Lombardi, Adolph V.</creatorcontrib><creatorcontrib>Berend, Keith R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical orthopaedics and related research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Barrington, John W.</au><au>Emerson, Roger H.</au><au>Lovald, Scott T.</au><au>Lombardi, Adolph V.</au><au>Berend, Keith R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA</atitle><jtitle>Clinical orthopaedics and related research</jtitle><stitle>Clin Orthop Relat Res</stitle><addtitle>Clin Orthop Relat Res</addtitle><date>2017-01-01</date><risdate>2017</risdate><volume>475</volume><issue>1</issue><spage>94</spage><epage>105</epage><pages>94-105</pages><issn>0009-921X</issn><eissn>1528-1132</eissn><abstract>Background
Opioid analgesics have been a standard modality for postoperative pain management after total knee arthroplasty (TKA) but are also associated with increased risk of nausea, pruritus, vomiting, respiratory depression, prolonged ileus, and cognitive dysfunction. There is still a need for a method of anesthesia that can deliver effective long-term postoperative pain relief without incurring the high cost and health burden of opioids and nerve blocks.
Questions/purposes
(1) Is liposomal bupivacaine-based periarticular injection (PAI) more effective than morphine-based spinal anesthesia or ropivacaine-based PAI in controlling postoperative pain after TKA? (2) Do patients treated with liposomal bupivacaine-based PAI experience fewer opioid-related adverse events compared with patients treated with morphine-based spinal anesthesia or ropivacaine-based PAI in controlling postoperative pain after TKA?
Methods
This multicenter, blind trial randomized 119 patients undergoing TKA with spinal anesthesia to receive spinal anesthesia plus periarticular injection with liposomal bupivacaine (40 patients), spinal anesthesia with bupivacaine plus intrathecal morphine (41 patients) but no liposomal bupivacaine injection, or spinal anesthesia with bupivacaine (38 patients) and no liposomal bupivacaine injection. The two groups that did not receive periarticular liposomal bupivacaine did receive periarticular injection with ropivacaine, and all three groups had ketorolac (30 mg) plus epinephrine (1:1000) in the periarticular injections. Patients in all three groups received identical perioperative multimodal analgesic and antiemetic drugs. All patients were analyzed in the group to which they were randomized and no patients were lost to followup. The primary study endpoints were visual analog score (VAS) for pain and narcotic use during postoperative day 1. Secondary endpoints included side effects associated with narcotic administration during the hospital stay.
Results
Mean VAS pain in the liposomal bupivacaine PAI group was lower than that for the ropivacaine PAI group at 6 hours (1.8 ± 2.1 versus 3.3 ± 2.3, p = 0.005, mean difference: 1.5, 95% confidence interval [CI], 0.5–2.5) and 12 hours (1.5 ± 2.0 versus 3.3 ± 2.4, p < 0.001, mean difference: 1.8, 95% CI, 0.8–2.8) after surgery. The morphine spinal group had lower pain compared with the liposomal bupivacaine PAI group at 6 hours (0.9 ± 1.8 versus 1.8 ± 2.1, p = 0.035, mean difference: 1.0, 95% CI, 0.1–1.8), but there was no difference at 12 hours (0.8 ± 1.5 versus 1.5 ± 2.0, p = 0.086, mean difference: 0.7, 95% CI, −0.1 to 1.5). The magnitude of the differences at 6 and 12 hours are near the lower end of minimal clinically important differences reported in the literature, and thus the improvement shown in this study may only represent a small clinical improvement. Both the liposomal bupivacaine group (13% [five of 40]) and the ropivacaine group (5% [two of 38]) had fewer incidents of itching (pruritus) than the spinal morphine group (38% [15 of 41]) (p = 0.001).
Conclusions
This prospective multicenter three-arm blind randomized controlled trial showed potentially improved pain control at 6 and 12 hours in the liposomal bupivacaine and intrathecal morphine groups compared with the ropivacaine group at the cost of much higher incidences of pruritus (itching) in the intrathecal morphine group. Based on these results, we prefer the use of PAI with liposomal bupivacaine as an alternative to spinal anesthesia with intrathecal morphine as a result of similar postoperative pain control and the potential for reducing adverse events.
Level of Evidence
Level I, therapeutic study.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>27339124</pmid><doi>10.1007/s11999-016-4931-z</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-921X |
ispartof | Clinical orthopaedics and related research, 2017-01, Vol.475 (1), p.94-105 |
issn | 0009-921X 1528-1132 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5174037 |
source | Open Access: PubMed Central |
subjects | Aged Analgesia, Patient-Controlled - methods Analgesics, Opioid - administration & dosage Analgesics, Opioid - therapeutic use Anesthetics, Local - administration & dosage Anesthetics, Local - therapeutic use Arthroplasty, Replacement, Knee - adverse effects Bupivacaine - administration & dosage Bupivacaine - therapeutic use Conservative Orthopedics Double-Blind Method Female Humans Injections, Spinal Liposomes Male Medicine Medicine & Public Health Middle Aged Morphine - administration & dosage Morphine - therapeutic use Orthopedics Pain Measurement Pain, Postoperative - drug therapy Sports Medicine Surgery Surgical Orthopedics Symposium: 2016 Knee Society Proceedings Treatment Outcome |
title | No Difference in Early Analgesia Between Liposomal Bupivacaine Injection and Intrathecal Morphine After TKA |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T20%3A35%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=No%20Difference%20in%20Early%20Analgesia%20Between%20Liposomal%20Bupivacaine%20Injection%20and%20Intrathecal%20Morphine%20After%20TKA&rft.jtitle=Clinical%20orthopaedics%20and%20related%20research&rft.au=Barrington,%20John%20W.&rft.date=2017-01-01&rft.volume=475&rft.issue=1&rft.spage=94&rft.epage=105&rft.pages=94-105&rft.issn=0009-921X&rft.eissn=1528-1132&rft_id=info:doi/10.1007/s11999-016-4931-z&rft_dat=%3Cproquest_pubme%3E1859497613%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c529t-d18b158497f15a441dec690c62540661eeca604ba5e527913552e05cf9d88b3f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1850692539&rft_id=info:pmid/27339124&rfr_iscdi=true |